EUVIMEDEUVIMED entdecken
Studienprotokoll

Developing a platform protocol for clinical trials evaluating interventions that target proposed mechanisms of Long COVID: RECOVER-VITAL

Kanecia O Zimmerman iD, Richard Whitley, Sean O'Brien, David R Walt, Bruce D Levy, Christine Maughan iD, Marta Cerda, Rachel Olson, Lucinda Bateman, Cyndya A Shibao, Barry Make, David Knopman und 8 weitere

Clinical Trials · 2026

DOI: 10.1177/17407745261422437 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Clinical Trials, 2026. Verfasst von Kanecia O Zimmerman und 19 weiteren Autor:innen. Beteiligte Einrichtung: Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Antiviral Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long COVID, the chronic sequela of SARS-CoV-2 infection, has affected millions of people worldwide. However, its pathogenesis and treatment remain unknown. To address this critical gap, the National Institutes of Health (NIH) developed the Researching COVID to Enhance Recovery (RECOVER) Initiative that included the Viral Persistence and Reactivation, and Immune Dysregulation (RECOVER-VITAL) study as one of the first of five NIH-sponsored, integrated platform protocols to support the rigorous and rapid investigation of potential interventions for Long COVID.

Methods

Experts across academia, the NIH, and the community of patients and caregivers were brought together to design the RECOVER-VITAL protocol. We present the challenges and rationale underpinning critical components of this protocol and provide evidence for use of the platform for efficient execution of current and future Long COVID clinical trials. Facets of the RECOVER-VITAL protocol, including inclusion criteria, intervention groups, study procedures, investigation of biomarkers, and endpoints, were carefully crafted to advance the current and future science and operations of Long COVID clinical trials, particularly in the absence of existing data. The initial trial within the RECOVER-VITAL platform evaluated two durations of an antiviral drug, nirmatrelvir/ritonavir, to test the proposed etiology of viral persistence on the Long COVID symptom clusters of autonomic dysfunction, cognitive dysfunction, and exercise intolerance. The primary outcome measures were patient-reported, and secondary outcomes included performance-based measures for each of the symptom clusters of interest.

Conclusions

The RECOVER-VITAL platform protocol has substantial implications for the design and conduct of future Long COVID clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicAntiviral AgentsHumansCOVID-19Post-Acute COVID-19 SyndromeSARS-CoV-2United StatesResearch DesignNational Institutes of Health (U.S.)Pandemics

Stichwörter der Autor:innen

Long COVIDPASCRECOVER-VITALnirmatrelvir/ritonavirplatform protocol

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
  • Departments of Pediatrics, Microbiology, Medicine, and Neurosurgery, Heersink School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
  • Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA.
  • Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • RECOVER Patient, Caregiver, or Community Representative, Durham, NC, USA.

ORCID-Profile: Kanecia O Zimmerman, Christine Maughan, Lisa Berdan

Förderung

  • National Institutes of Health

Zitieren

APA

Zimmerman, K. O., Whitley, R., O'Brien, S., Walt, D. R., Levy, B. D., Maughan, C., Cerda, M., Olson, R., Bateman, L., Shibao, C. A., Make, B., Knopman, D., Redline, S., Jason, L. A., Suthar, M. S., Low, P., Nolen, T. L., Reist, C., Berdan, L., & Baden, L. R. (2026). Developing a platform protocol for clinical trials evaluating interventions that target proposed mechanisms of Long COVID: RECOVER-VITAL. Clinical Trials. https://doi.org/10.1177/17407745261422437

Vancouver

Zimmerman KO, Whitley R, O'Brien S, Walt DR, Levy BD, Maughan C, et al. Developing a platform protocol for clinical trials evaluating interventions that target proposed mechanisms of Long COVID: RECOVER-VITAL. Clinical Trials. 2026. doi:10.1177/17407745261422437

BibTeX
@article{Zimmerman2026,
  author = {Zimmerman, Kanecia O and Whitley, Richard and O'Brien, Sean and Walt, David R and Levy, Bruce D and Maughan, Christine and Cerda, Marta and Olson, Rachel and Bateman, Lucinda and Shibao, Cyndya A and Make, Barry and Knopman, David and Redline, Susan and Jason, Leonard A and Suthar, Mehul S and Low, Phillip and Nolen, Tracy L and Reist, Craig and Berdan, Lisa and Baden, Lindsey R},
  title = {Developing a platform protocol for clinical trials evaluating interventions that target proposed mechanisms of Long COVID: RECOVER-VITAL},
  journal = {Clinical Trials},
  year = {2026},
  doi = {10.1177/17407745261422437}
}
Kostenlos starten →